Overview

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Phase 2 trial to study FL-101 alone or in combination with nivolumab in patients who have surgically resectable Non-Small Cell Lung Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Flame Biosciences
Treatments:
Nivolumab